NCT01483846View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Neuropathic Pain
Interventions
DRUG

AV-101

Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.

DRUG

Placebo

Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.

Trial Locations (1)

92037

UCSD Medical Center, San Diego

Sponsors

Collaborators (1)

Cato Research
All Listed Sponsors
collaborator

Cato Research

INDUSTRY

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

VistaGen Therapeutics, Inc.

INDUSTRY

NCT01483846 - Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers | Biotech Hunter | Biotech Hunter